| Market Capitalization (Millions $) |
18 |
| Shares
Outstanding (Millions) |
52 |
| Employees |
401 |
| Revenues (TTM) (Millions $) |
27 |
| Net Income (TTM) (Millions $) |
-21 |
| Cash Flow (TTM) (Millions $) |
-5 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Enzo Biochem Inc. is a global biotechnology company that specializes in the development and commercialization of innovative life science research tools, clinical diagnostic products, and therapeutic offerings. The company has been involved in the field of biomedical research for over 40 years and has established itself as a leading player in the industry.
The company operates through three main units: Enzo Life Sciences, Enzo Clinical Labs, and Enzo Therapeutics. Enzo Life Sciences is dedicated to developing and providing a wide range of high-quality research reagents, assay kits, and platforms to enable scientists to better understand diseases and develop new treatments. The company's product portfolio includes more than 40,000 high-performance antibodies, proteins, peptides, and small molecules that are used in numerous research areas, including cancer, cardiovascular disease, neurodegeneration, infectious diseases, and genomics.
Enzo Clinical Labs is a full-service clinical laboratory that provides an array of advanced diagnostic testing services to physicians, patients, and hospitals across the U.S. The company specializes in testing for gastrointestinal, endocrine, and infectious diseases, as well as cancer, genetic disorders, and drug monitoring. Enzo Clinical Labs has received numerous accreditations and certifications from leading organizations, including the College of American Pathologists (CAP), CLIA, and the New York State Department of Health.
Enzo Therapeutics is focused on developing innovative therapeutic products for the treatment of cancer, autoimmune, and inflammatory disorders. The company has a pipeline of novel small molecules and biologics that target specific disease pathways and have the potential to provide more effective therapies with fewer side effects than traditional treatments.
Enzo Biochem has a strong intellectual property portfolio, with over 270 issued patents worldwide covering a wide range of technologies, including nucleic acid labeling, detection, and quantification, recombinant protein production, and monoclonal antibody-based products. The company has also formed strategic partnerships with leading academic and commercial organizations to develop new products and technologies.
Enzo Biochem has a diverse customer base ranging from academic researchers to biotech and pharmaceutical companies, clinical laboratories, and healthcare providers. The company has a global presence with operations in the U.S., Europe, and Asia and sells its products and services in more than 100 countries worldwide.
The company has a strong financial position, with revenues of $101 million in fiscal year 2020 and a net income of $2 million. The company has a market capitalization of approximately $118 million and is traded on the New York Stock Exchange under the ticker symbol ENZ.
In summary, Enzo Biochem Inc is a well-established and respected biotech company that is focused on developing and commercializing innovative life science research tools, clinical diagnostic products, and therapeutic offerings. With a strong product pipeline, intellectual property portfolio, and global presence, the company is well-positioned to continue to grow and succeed in the dynamic and competitive biotech industry.
Company Address: 81 Executive Blvd New York 11735 NY
Company Phone Number: 755-5500 Stock Exchange / Ticker: NYSE ENZ
|
1.22%